SAN.PA : Summary for SANOFI - Yahoo Finance

U.S. Markets closed

Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
76.33+1.25 (+1.66%)
At close: 11:35 AM EST
People also watch:
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close75.08
Open75.32
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range75.28 - 76.95
52 Week Range62.50 - 80.90
Volume3,046,253
Avg. Volume2,870,628
Market Cap96.68B
BetaN/A
PE Ratio (TTM)23.42
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Inovio Pharmaceuticals, Inc.'s Biggest Win in 2016
    Motley Fool2 hours ago

    Inovio Pharmaceuticals, Inc.'s Biggest Win in 2016

    Inovio had a setback with its cervical dysplasia vaccine program, but the biotech also had a huge win this year.

  • EMA Reviews Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (ADR) (SNY) Dupixent MAA
    Insider Monkey3 hours ago

    EMA Reviews Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (ADR) (SNY) Dupixent MAA

    The European Medicines Agency (EMA) has recently accepted to review the Marketing Authorization Application (MAA) of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) for Dupixent (dupilumab) as a treatment for adult moderate-to-severe atopic dermatitis (AD) patients who are systemic therapy candidates. Dupixent is an investigational biologic therapy that inhibits the signaling of two […]

  • The Wall Street Journal9 hours ago

    Bayer Teams Up With Versant to Develop Stem-Cell Therapies

    Bayer and U.S. healthcare investor Versant Ventures plan to establish a stem-cell research company called BlueRock Therapeutics, with initial joint funding of $225 million.